Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide. As a vasopressin receptor 2 antagonist, tolvaptan is the FDA-approved therapeutic agent for ADPKD, which is only made available...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-07-01
|
| Series: | Kidney Diseases |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/517186 |